Home
About Us
Company Overview
Innovation and Leadership
Products
Discovery
Company Highlights
Company History
Our People
Senior Management
Our Reach
Awards and Recognition
Australian Industry Participation Purchasing Policy
Positions Vacant
Legal Disclaimer
Our Products
Aridol
Current clinical trials
Aridol Distributors
Bronchitol
Current clinical trials
Bronchitol Product Information
Bronchitol Distributors
Respiratory Diseases
Named Patient Program (Compassionate Use)
Scientific Publications
Patents
Investors
ASX Announcements
ASX 2012
ASX 2011
ASX 2010
ASX 2009
ASX 2008
ASX 2007
ASX 2006
ASX 2005
ASX 2004
ASX 2003
News
Quarterly Reports
Annual Reports
Investor Presentations
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Share Price
Shareholder Services
Join Our Mailing List
Contact Us
Events Calendar
Financial Summary
Analyst Coverage
Shareholders
Corporate Directory
Corporate Governance
SEC Filings
Pharmaxis ADRs
News
Media Releases
Media 2012
Media 2011
Media 2010
Media 2009
Media 2008
Media 2007
Media 2006
Media 2005
Media 2004
Media 2003
Quarterly Reports
Quarterly Reports 2012
Quarterly Reports 2011
Quarterly Reports 2010
Quarterly Reports 2009
Quarterly Reports 2008
Quarterly Reports 2007
Quarterly Reports 2006
Quarterly Reports 2005
Quarterly Reports 2004
Media Contact
News Feeds
New Product Pipeline
Clinical Trials
Scientific Publications
Investigator-Initiated Studies
Respiratory diseases
Patents
Contact Us
Health Professionals
Patients
Media 2009
Pharmaxis receives response letter from the FDA on Aridol application
Pharmaxis lodges TGA application to market Bronchitol™ for CF in Australia
Pharmaxis Announces Sustained Benefit with Bronchitol in Phase 3 Cystic Fibrosis Trial
FDA Advisory Committee Recommends Approval of Aridol
Pharmaxis Applies to Market Bronchitol for Cystic Fibrosis in Europe
Pharmaxis Commences Pivotal Bronchiectasis Study and Aligns Global Registration Strategy
Chairman's Address to AGM
Recording of Investor Conference Call - 15 October 2009
Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
Second Cystic Fibrosis Trial Passes Recruitment Target
Pharmaxis to Present at European Respiratory Society Meeting
Recording of Investor Conference Call - 23 July 2009
Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
Pharmaxis to Voluntarily De-List from Nasdaq
Pharmaxis Closes Share Purchase Plan
Archived News
Pharmaxis
Home
Media 2009
Chairman's Address to AGM
21.10.2009 - Chairman's Address to AGM
Chairman's Address to the 2009 Annual General Meeting held on 21 October 2009
Download Document
Back to Latest News